Immunotherapy related myocarditis, colitis, uveitis, or pneumonitis.
No prior immunotherapy for advanced/metastatic MCC
Prior treatment with immunotherapy
Immunotherapy
Prior immunotherapy is allowed.
Participants in all combination therapy arms must not have a history of exposure to an immunotherapy experiencing an immune-mediated adverse event that required permanent discontinuation of the immunotherapy.
Concurrent immunotherapy is allowed
Immunotherapy less than or equal to  weeks prior to registration
Prior immunotherapy including sipuleucel-T
Previous use of investigational agents, chemotherapy or immunotherapy for lymphoma any time prior to enrollment (i.e. must have untreated disease); prior allogeneic or autologous transplants are also not allowed
Prior treatment with any immunotherapy
Must have completely recovered or recovered to baseline prior to screening from any prior AEs occurring while receiving prior immunotherapy.
Received chemotherapy/immunotherapy in the last  weeks
For post immunotherapy patients with NSCLC all of the following apply:
For other post immunotherapy patients all of the following must apply:
Actively receiving chemo-immunotherapy
History of active immunotherapy in the previous month.
Phase II only: patients with colorectal cancer with known microsatellite instability (MSI)-high disease who have previously been treated with immunotherapy or who have refused treatment with immunotherapy
Patients who have received any prior immunotherapy
Patients that have undergone Tyrosinase immunotherapy
Immunotherapy-naive.
Subjects who have received prior PSA, MUC, and/or brachyury-targeted immunotherapy (e.g. vaccine) are eligible for this trial if this treatment was discontinued at least  months prior to enrollment
Prior treatment with adenovirus-based vectors immunotherapy
Cohort #: received only frontline CD-directed immunotherapy with anthracycline- or anthracenedione-based multi-agent chemotherapy for patients with DLBCL; monotherapy rituximab or other CD-directed immunotherapy prior to frontline chemotherapy, as maintenance therapy, and radiotherapy in a limited field or as a part of the frontline treatment plan are permitted; last treatment dose should be  weeks before start of study treatment
Chemotherapy or immunotherapy within  weeks prior to start of huF
History of prior immunotherapy within the last  years (immunotherapy allowed for lead-in cohort in castration resistant disease)
Patients with prior salvage chemo-immunotherapy, radiation therapy, autologous transplantation are included
Prior immunotherapy including sipuleucel-T
Chemotherapy or immunotherapy =<  days prior to registration
Patients may have had no more than one prior line of chemotherapy or immunotherapy in the metastatic setting; at least  days must have elapsed from the last chemo/immunotherapy administration until the start of protocol treatment, and patients must have recovered from the side effects of any of these agents
Received systemic treatment for cancer, including immunotherapy, within  days prior to initiation of conditioning chemotherapy administration within this protocol
Patients may have received prior immunotherapy
Prior chemotherapy or immunotherapy will be allowed if new or persistent measurable site(s) of disease are present
Prior immunotherapy or chemotherapy is allowed as long as >  days prior to enrollment
Chemotherapy, biochemotherapy, radiation or immunotherapy or any investigational treatment within  days prior to receiving any study drug.
Any prior systemic anti-cancer immunotherapy treatment
Chemotherapy or immunotherapy within  weeks prior to the first dose of vaccine
Prior chemotherapy, radiation, sipuleucel-T or other experimental immunotherapy less than  weeks prior to the start of study medication.
Received systemic treatment for cancer, including immunotherapy, within one month prior to initiation of dosing within this protocol
Ongoing systemic therapy for prostate cancer including, but not limited to:\r\n\t* Immunotherapy (e.g. sipuleucel-T, ipilimumab)\r\n\t* Non-protocol prescribed chemotherapy (e.g. cabazitaxel)
Be within  months (+/- week) between last dose of an immunotherapy agent and study enrollment\r\n* Patients may continue with maintenance immunotherapy as part of standard of care therapy while receiving radiation
No prior chemotherapy, targeted therapy, or immunotherapy for mesothelioma
Ongoing immunotherapy (checkpoint inhibition, antigen immunotherapy that would be scheduled to continue concomitantly to the study).
No restriction based on prior treatments but at least  weeks from prior immunotherapy, or prior investigational agents
No prior receipt of systemic treatment (chemotherapy, targeted therapy, or immunotherapy) for the lesion under consideration of treatment
Have received biologic therapy, including immunotherapy, <  days prior to CD;
Immunotherapy (e.g. tumor vaccine) (At least  days since last dose of immunotherapy agent(s) prior to first dose of tazemetostat)
Previous use of indoximod or tergenpumatucel-L immunotherapy.
Patients that have previously progressed on immunotherapy such as ipilimumab will be eligible
Previous chemotherapy/immunotherapy within  weeks before study entry
Chemotherapy, biologics, immunotherapy, vaccine, cytokine therapy within  weeks prior to enrollment
Previous treatment with surgery, radiation, chemotherapy, immunotherapy or any targeted agents are allowed provided that: \r\n* Chemotherapy was administered >  days before the start of HD IL-\r\n* Surgery, radiation, immunotherapy or any targeted agents was administered >  days before the start of HD IL-
Patients who have received prior immunotherapy
No chemotherapy or immunotherapy for a minimum of three weeks prior to start of huF
Prior neurologic toxicity to previous immunotherapy
Those receiving prior immunotherapy must meet all of the following conditions:
Patients who have received prior immunotherapy
Prior treatment with other immunotherapy, including antibodies, is allowed
>=  weeks between completion of chemotherapy or immunotherapy and first (st) vaccination
Subjects who have received prior immunotherapy may be eligible
Patients must have received previous systemic therapy to include: a regimen of chemotherapy, immunotherapy including anti-PDL or anti-PD-L therapies, combined chemotherapy and immunotherapy, provided treatment was discontinued >=  weeks prior to initiation of treatment on the present protocol
Systemic chemotherapy or immunotherapy within  days of enrollment;
Any prior immunotherapy or vaccine therapy
Antibodies or immunotherapy within  weeks before the first dose of study treatment.
Prior immunotherapy
Prior investigational immunotherapy
Immunotherapy (e.g., tumor vaccine) At least  weeks since last dose of immunotherapy agent(s) prior to first dose of tazemetostat)
Received only frontline CD-directed immunotherapy with anthracycline- or anthracenedione-based multi-agent chemotherapy. Monotherapy rituximab or other CD-directed immunotherapy as maintenance therapy prior to frontline chemotherapy, and radiotherapy in a limited field or as part of the frontline treatment plan are permitted.
Prior platinum chemotherapy or immunotherapy
Treatment with immunotherapy against PCa within the previous  months prior to randomization
Previous immunotherapy
History of listeriosis or previous treatment with a listeria-based immunotherapy
More than one chemotherapeutic regimen given for R/M disease. Prior treatment with immunotherapy is allowed.
Prior treatment with other next generation anti-androgens or other CYP inhibitors, immunotherapy or radiopharmaceutical agents for prostate cancer
EXCLUSION FOR TREATMENT: Prior neurologic toxicity to previous immunotherapy
Prior immunotherapy with CRS- or any other Listeria-based agent, therapeutic cancer vaccine, or adoptive T cell immunotherapy
Prior immunotherapy will be permitted; however, any prior immunotherapy must be discontinued at least  weeks before peptide vaccine administration; non-immunologic therapy may be continued
Received systemic treatment for cancer, including immunotherapy, within one month prior to initiation of dosing within this protocol
Prior chemotherapy, immunotherapy, or targeted therapy is allowed as long as it did not include dasatinib
Immunotherapy [mAbs, Interferons, Cytokines (except GCSF)]
Subjects who have received prior CEA, MUC, and/or brachyury-targeted immunotherapy (vaccine) are eligible for this trial if this treatment was discontinued at least  weeks prior to enrollment
Participation in any other immunotherapy treatment, that in the opinion of the principal investigator would be unsafe to receive further checkpoint blockade immunotherapy.
History of prior immunotherapy within the last  years
Prior systemic cytotoxic chemotherapies and/or novel immunotherapy treatments for MCC are allowed. A wash-out period of  weeks prior to aNK treatment will be required.
The patient must not have received any immunotherapy for their brain tumor
Immunotherapy within the  days prior to randomization
Any immunotherapy within  weeks of first dose of study drug.
Most recent chemotherapy, immunotherapy, chemo-immunotherapy, or investigational agents < days of the first dose of study treatment. Most recent targeted therapy < days of the first dose of study treatment.
Received any other therapeutic investigational agent within  days of screening, except for immunotherapy. Patients with previous immunotherapy are not eligible regardless of timing.
Any immunotherapy within  weeks of first dose of study drug.
Willingness to discontinue any cytotoxic chemotherapeutic agents, immunotherapy and biologic therapy at least  weeks prior to the start of RT.
Immunotherapy within  days prior to signing consent
Nave untreated patients or patients who have progressed on or after prior first line immunotherapy for resectable locally advanced or metastatic melanoma; prior adjuvant therapy is permitted (e.g. IFN, IL- therapy, any other immunotherapy, radiotherapy or chemotherapy), except the administration of BRAF or MEK inhibitors
Any previous systemic chemotherapy treatment, extensive radiotherapy or investigational agent other than immunotherapy, or patients who have received more than one line of immunotherapy for locally advanced unresectable or metastatic melanoma; Ipilimumab (adjuvant) or other immunotherapy treatment must have ended at least  weeks prior to randomization
History of prior immunotherapy within the last  years
Treatment with an immunotherapy within  days
Prior sipuleucel-T treatment or investigational immunotherapy.
Patients with washout period <  weeks from the last dose of ipilimumab or other immunotherapy.
No chemotherapy or immunotherapy for a minimum of three weeks prior to study enrollment
Previous immunotherapy treatment for metastatic disease in the preceding  months; Note: immunotherapy in the adjuvant setting is allowed
ELIGIBILITY PRIOR TO POST-CHEMOTHERAPY IMMUNOTHERAPY:
Patients with washout period <  weeks from the last dose of ipilimumab or other immunotherapy
Prior immunotherapy is allowed
Subjects who have received certain prior immunotherapy or had toxicities relating to prior immunotherapy may not be permitted to enroll. o Must not have required the use of additional immunosuppression other than corticosteroids for the management of an adverse event.
Immunotherapy =<  days prior to pre-registration (e.g. intravesical Bacillus Calmette-Guerin [BCG])
Any previous systemic therapy for B-cell NHL, including chemotherapy, immunotherapy, or steroids
History of any of the following toxicities associated with a prior immunotherapy:
Immunotherapy within  days prior to randomization
Immunotherapy for cancer within  weeks of initial study treatment
Immunotherapy within  days prior to randomization.
Patients may have had prior chemotherapy or immunotherapy (vaccines, interferon, ipilimumab, or IL-) with progression or persistent disease
Subjects may have received previous courses of an investigational biologic therapy including active or passive immunotherapy greater than  days prior to receiving the first injection of DPX-Survivac
melanoma: at least  prior treatment (including immunotherapy).
The participant received prior immunotherapy and is experiencing or has experienced any of the following (OLE cohort only):
The participant received prior immunotherapy and at the time of study enrollment, requires steroids or other immunosuppressive agents (OLE cohort only).
prior immunotherapy
Immunotherapy: ? days after completion of immunotherapy
